
Andrew Hill

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5503865/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	High individual pain variability in people living with HIV: A graphical analysis. European Journal of Pain, 2021, 25, 160-170.	2.8	0
2	Unexpected interactions between dolutegravir and folate: randomized trial evidence from South Africa. Aids, 2021, 35, 205-211.	2.2	11
3	Risks of metabolic syndrome and diabetes with integrase inhibitor-based therapy. Current Opinion in Infectious Diseases, 2021, 34, 16-24.	3.1	20
4	Risks of metabolic syndrome and diabetes with integrase inhibitor-based therapy: Republication. Current Opinion in HIV and AIDS, 2021, 16, 106-114.	3.8	7
5	The predicted risk of adverse pregnancy outcomes as a result of treatment-associated obesity in a hypothetical population receiving tenofovir alafenamide/emtricitabine/dolutegravir, tenofovir disoproxil fumarate/emtricitabine/dolutegravir or tenofovir disoproxil fumarate/emtricitabine/dolutegravir. Aids. 2021. 35. S117-S125.	2.2	12
6	Adherence, resistance, and viral suppression on dolutegravir in sub-Saharan Africa: implications for the TLD era. Aids, 2021, 35, S127-S135.	2.2	21
7	Time to rethink endpoints for new clinical trials of antiretrovirals? Long-term re-suppression of HIV RNA with integrase inhibitors. Aids, 2020, 34, 321-324.	2.2	4
8	Dolutegravir with emtricitabine and tenofovir alafenamide or tenofovir disoproxil fumarate versus efavirenz, emtricitabine, and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection (ADVANCE): week 96 results from a randomised, phase 3, non-inferiority trial. Lancet HIV,the, 2020, 7, e666-e676.	4.7	145
9	Phase 3 trials of new antiretrovirals are not representative of the global HIV epidemic. Journal of Virus Eradication, 2020, 6, 70-73.	0.5	20
10	Tenofovir alafenamide vs. tenofovir disoproxil fumarate: an updated meta-analysis of 14 894 patients across 14 trials. Aids, 2020, 34, 2259-2268.	2.2	30
11	Reduced efficacy of HIV-1 integrase inhibitors in patients with drug resistance mutations in reverse transcriptase. Nature Communications, 2020, 11, 5922.	12.8	55
12	Phase 3 trials of new antiretrovirals are not representative of the global HIV epidemic. Journal of Virus Eradication, 2020, 6, 70-73.	0.5	4
13	Optimizing responses to drug safety signals in pregnancy: the example of dolutegravir and neural tube defects. Journal of the International AIDS Society, 2019, 22, e25352.	3.0	25
14	Dolutegravir plus Two Different Prodrugs of Tenofovir to Treat HIV. New England Journal of Medicine, 2019, 381, 803-815.	27.0	447
15	The transition to dolutegravir and other new antiretrovirals in low-income and middle-income countries. Aids, 2018, 32, 1551-1561.	2.2	96